A citation-based method for searching scientific literature

Martin Schlumberger, Marie-Hélène Massicotte, Camila L Nascimento, Cécile Chougnet, Eric Baudin, Sophie Leboulleux. Clinics (Sao Paulo) 2012
Times Cited: 14







List of co-cited articles
65 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
865
57

Medullary thyroid cancer: management guidelines of the American Thyroid Association.
Richard T Kloos, Charis Eng, Douglas B Evans, Gary L Francis, Robert F Gagel, Hossein Gharib, Jeffrey F Moley, Furio Pacini, Matthew D Ringel, Martin Schlumberger,[...]. Thyroid 2009
815
50

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
673
35

Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Laurie L Carr, David A Mankoff, Bernardo H Goulart, Keith D Eaton, Peter T Capell, Elizabeth M Kell, Julie E Bauman, Renato G Martins. Clin Cancer Res 2010
286
28

Lenvatinib versus placebo in radioiodine-refractory thyroid cancer.
Martin Schlumberger, Makoto Tahara, Lori J Wirth, Bruce Robinson, Marcia S Brose, Rossella Elisei, Mouhammed Amir Habra, Kate Newbold, Manisha H Shah, Ana O Hoff,[...]. N Engl J Med 2015
974
28

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
21

Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage.
Yuji Yamamoto, Junji Matsui, Tomohiro Matsushima, Hiroshi Obaishi, Kazuki Miyazaki, Katsuji Nakamura, Osamu Tohyama, Taro Semba, Atsumi Yamaguchi, Sachi Suzuki Hoshi,[...]. Vasc Cell 2014
241
21

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. J Clin Oncol 2010
351
21

Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features.
G Bunone, P Vigneri, L Mariani, S Butó, P Collini, S Pilotti, M A Pierotti, I Bongarzone. Am J Pathol 1999
325
21

Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models.
Osamu Tohyama, Junji Matsui, Kotaro Kodama, Naoko Hata-Sugi, Takayuki Kimura, Kiyoshi Okamoto, Yukinori Minoshima, Masao Iwata, Yasuhiro Funahashi. J Thyroid Res 2014
243
21

Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis.
Cristina Rodríguez-Antona, Judith Pallares, Cristina Montero-Conde, Lucia Inglada-Pérez, Esmeralda Castelblanco, Iñigo Landa, Susanna Leskelä, Luis J Leandro-García, Elena López-Jiménez, Rocío Letón,[...]. Endocr Relat Cancer 2010
87
21

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
Marcia S Brose, Christopher M Nutting, Barbara Jarzab, Rossella Elisei, Salvatore Siena, Lars Bastholt, Christelle de la Fouchardiere, Furio Pacini, Ralf Paschke, Young Kee Shong,[...]. Lancet 2014
858
21

Natural history, diagnosis, treatment and outcome of medullary thyroid cancer: 37 years experience on 157 patients.
M R Pelizzo, I M Boschin, P Bernante, A Toniato, A Piotto, C Pagetta, O Nibale, L Rampin, P C Muzzio, D Rubello. Eur J Surg Oncol 2007
133
14

Counselling in multiple endocrine neoplasia syndromes: from individual experience to general guidelines.
C J Lips, J W Höppener, B P Van Nesselrooij, R B Van der Luijt. J Intern Med 2005
21
14

Hypercalcitoninemia is not pathognomonic of medullary thyroid carcinoma.
Sergio P A Toledo, Delmar M Lourenço, Marcelo Augusto Santos, Marcos R Tavares, Rodrigo A Toledo, Joya Emilie de Menezes Correia-Deur. Clinics (Sao Paulo) 2009
78
14

Immunohistochemistry of medullary thyroid carcinoma and C-cell hyperplasia by an affinity-purified anti-human calcitonin antiserum.
C Y Hayashida, V A Alves, C T Kanamura, M C Ezabella, N M Abelin, W Nicolau, H Bisi, S P Toledo. Cancer 1993
13
15

Impact of RET proto-oncogene analysis on the clinical management of multiple endocrine neoplasia type 2.
Sergio Pereira de Almeida Toledo, Marcelo Augusto Cortina Gonçalves dos Santos, Rodrigo de Almeida Toledo, Delmar Muniz Lourenço. Clinics (Sao Paulo) 2006
36
14

Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10.
Karin Frank-Raue, Lisa A Rybicki, Zoran Erlic, Heiko Schweizer, Aurelia Winter, Ioana Milos, Sergio P A Toledo, Rodrigo A Toledo, Marcos R Tavares, Maria Alevizaki,[...]. Hum Mutat 2011
81
14

Multiple endocrine neoplasia type 2: achievements and current challenges.
Andreas Machens, Henning Dralle. Clinics (Sao Paulo) 2012
19
14

High penetrance of pheochromocytoma associated with the novel C634Y/Y791F double germline mutation in the RET protooncogene.
Rodrigo A Toledo, Simona M Wagner, Flavia L Coutinho, Delmar M Lourenço, Juliana A Azevedo, Viviane C Longuini, Mariana T A Reis, Sheila A C Siqueira, Antonio M Lucon, Marcos R Tavares,[...]. J Clin Endocrinol Metab 2010
41
14

[Early detection of medullary thyroid carcinoma in multiple endocrine neoplasia type II].
M C Ezabella, C Y Hayashida, H Bisi, M O Leite, A Borelli, N M Abelin, A C Cordeiro, R Y Camargo, S P Toledo. Rev Hosp Clin Fac Med Sao Paulo 1990
4
50

Guidelines for diagnosis and therapy of MEN type 1 and type 2.
M L Brandi, R F Gagel, A Angeli, J P Bilezikian, P Beck-Peccoz, C Bordi, B Conte-Devolx, A Falchetti, R G Gheri, A Libroia,[...]. J Clin Endocrinol Metab 2001
14

The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis.
C Eng, D Clayton, I Schuffenecker, G Lenoir, G Cote, R F Gagel, H K van Amstel, C J Lips, I Nishisho, S I Takai,[...]. JAMA 1996
776
14

Clinical predictors and algorithm for the genetic diagnosis of pheochromocytoma patients.
Zoran Erlic, Lisa Rybicki, Mariola Peczkowska, Henriette Golcher, Peter H Kann, Michael Brauckhoff, Karsten Müssig, Michaela Muresan, Andreas Schäffler, Nicole Reisch,[...]. Clin Cancer Res 2009
124
14

The impact of clinical and genetic screenings on the management of the multiple endocrine neoplasia type 1.
Delmar Muniz Lourenço, Rodrigo Almeida Toledo, Flavia Lima Coutinho, Leontina Conceição Margarido, Sheila Aparecida Coelho Siqueira, Marcelo Augusto Cortina Gonçalves dos Santos, Fabio Luiz de Menezes Montenegro, Marcel Cerqueira Cesar Machado, Sergio Pereira Almeida Toledo. Clinics (Sao Paulo) 2007
56
14


Sporadic medullary thyroid carcinoma: clinical data from a university hospital.
Joya Emilie M Correia-Deur, Rodrigo A Toledo, Alice T Imazawa, Delmar M Lourenço, Marilza C L Ezabella, Marcos R Tavares, Sergio P A Toledo. Clinics (Sao Paulo) 2009
11
18

RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors.
Jan Willem B de Groot, Thera P Links, John T M Plukker, Cornelis J M Lips, Robert M W Hofstra. Endocr Rev 2006
231
14

New treatment in advanced thyroid cancer.
Dario Giuffrida, Angela Prestifilippo, Alessia Scarfia, Daniela Martino, Stefania Marchisotta. J Oncol 2012
11
18

Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population.
Merina Ahmed, Yolanda Barbachano, Angela Riddell, Jen Hickey, Katie L Newbold, Amaya Viros, Kevin J Harrington, Richard Marais, Christopher M Nutting. Eur J Endocrinol 2011
153
14


High prevalence of RAS mutations in RET-negative sporadic medullary thyroid carcinomas.
Margarida M Moura, Branca M Cavaco, António E Pinto, Valeriano Leite. J Clin Endocrinol Metab 2011
153
14

Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes.
Cristina Romei, Stefano Mariotti, Laura Fugazzola, Augusto Taccaliti, Furio Pacini, Giuseppe Opocher, Caterina Mian, Maurizio Castellano, Ettore degli Uberti, Isabella Ceccherini,[...]. Eur J Endocrinol 2010
89
14

Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study.
Rossella Elisei, Barbara Cosci, Cristina Romei, Valeria Bottici, Giulia Renzini, Eleonora Molinaro, Laura Agate, Agnese Vivaldi, Pinuccia Faviana, Fulvio Basolo,[...]. J Clin Endocrinol Metab 2008
324
14

RET TKI: potential role in thyroid cancers.
Alessandro Antonelli, Poupak Fallahi, Silvia Martina Ferrari, Caterina Mancusi, Michele Colaci, Libero Santarpia, Clodoveo Ferri. Curr Oncol Rep 2012
39
14

Targeting the RET pathway in thyroid cancer.
Samuel A Wells, Massimo Santoro. Clin Cancer Res 2009
124
14

Sunitinib: from rational design to clinical efficacy.
Laura Q M Chow, S Gail Eckhardt. J Clin Oncol 2007
666
14

Targeted therapy of thyroid cancer.
Steven I Sherman. Biochem Pharmacol 2010
57
14

Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy.
C Durante, N Haddy, E Baudin, S Leboulleux, D Hartl, J P Travagli, B Caillou, M Ricard, J D Lumbroso, F De Vathaire,[...]. J Clin Endocrinol Metab 2006
932
14

Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study.
Keith C Bible, Vera J Suman, Julian R Molina, Robert C Smallridge, William J Maples, Michael E Menefee, Joseph Rubin, Kostandinos Sideras, John C Morris, Bryan McIver,[...]. Lancet Oncol 2010
308
14

Motesanib diphosphate in progressive differentiated thyroid cancer.
Steven I Sherman, Lori J Wirth, Jean-Pierre Droz, Michael Hofmann, Lars Bastholt, Renato G Martins, Lisa Licitra, Michael J Eschenberg, Yu-Nien Sun, Todd Juan,[...]. N Engl J Med 2008
355
14

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial.
Sophie Leboulleux, Lars Bastholt, Thomas Krause, Christelle de la Fouchardiere, Jan Tennvall, Ahmad Awada, José Manuel Gómez, Françoise Bonichon, Laurence Leenhardt, Christine Soufflet,[...]. Lancet Oncol 2012
244
14

Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer.
David S Cooper, Gerard M Doherty, Bryan R Haugen, Richard T Kloos, Stephanie L Lee, Susan J Mandel, Ernest L Mazzaferri, Bryan McIver, Furio Pacini, Martin Schlumberger,[...]. Thyroid 2009
14

Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
Razelle Kurzrock, Steven I Sherman, Douglas W Ball, Arlene A Forastiere, Roger B Cohen, Ranee Mehra, David G Pfister, Ezra E W Cohen, Linda Janisch, Forlisa Nauling,[...]. J Clin Oncol 2011
411
14

Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.
Alan L Ho, Ravinder K Grewal, Rebecca Leboeuf, Eric J Sherman, David G Pfister, Desiree Deandreis, Keith S Pentlow, Pat B Zanzonico, Sofia Haque, Somali Gavane,[...]. N Engl J Med 2013
475
14

The noninvestigational use of tyrosine kinase inhibitors in thyroid cancer: establishing a standard for patient safety and monitoring.
Aubrey A Carhill, Maria E Cabanillas, Camilo Jimenez, Steven G Waguespack, Mouhammed A Habra, Mimi Hu, Anita Ying, Rena Vassilopoulou-Sellin, Robert F Gagel, Steven I Sherman,[...]. J Clin Endocrinol Metab 2013
52
14

A phase II trial of fosbretabulin in advanced anaplastic thyroid carcinoma and correlation of baseline serum-soluble intracellular adhesion molecule-1 with outcome.
Colin J Mooney, Govardhanan Nagaiah, Pingfu Fu, Jay K Wasman, Matthew M Cooney, Panos S Savvides, Joseph A Bokar, Afshin Dowlati, Ding Wang, Sanjiv S Agarwala,[...]. Thyroid 2009
135
14

Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
Elaine T Lam, Matthew D Ringel, Richard T Kloos, Thomas W Prior, Michael V Knopp, Jiachao Liang, Steffen Sammet, Nathan C Hall, Paul E Wakely, Vasyl V Vasko,[...]. J Clin Oncol 2010
276
14


Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Ezra E W Cohen, Lee S Rosen, Everett E Vokes, Merrill S Kies, Arlene A Forastiere, Francis P Worden, Madeleine A Kane, Eric Sherman, Sinil Kim, Paul Bycott,[...]. J Clin Oncol 2008
463
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.